ELCC 2019 Newsroom

Personal Highlights

Interview with Prof. Solange Peters
Watch the video interview here >>>

Interview with Prof. Nicolas Girard
Watch the video interview here >>>

Interview with Prof. Tony Mok
Watch the video interview here >>>

Interview with Prof. Jürgen Wolf
Watch the video interview here >>>

Interview with Dr Sanjay Popat
Watch the video interview here >>>

Study Highlights
Non-Small Cell Lung Cancer
KEYNOTE-042: First-line pembrolizumab therapy is superior to chemotherapy in patients with PD-L1 expressing NSCLC
At ELCC 2019, Prof. Mok presented the final analysis of the phase III KEYNOTE-042 trial. In this study, a total of 1,274 patients with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) without EGFR/ALK alterations were randomised 1:1 to receive either 200 mg pembrolizumab every 3 weeks for up to 35 cycles or a chemotherapy regimen consisting of carboplatin (AUC 5 or 6) plus paclitaxel (200 mg/m2) or carboplatin (AUC 5 or 6) plus pemetrexed (500 mg/m2) every 3 weeks for up to 6 cycles. 
Read more
Reference: Mok et al. 2019. Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC. Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Non-Small Cell Lung Cancer
Increased OS benefit with durvalumab in the post-study analysis of MYSTIC
The primary analysis of the MYSTIC trial (N=1,118) showed that first-line immunotherapy consisting of durvalumab or the combination of durvalumab plus tremelimumab did not improve overall survival (OS) in unselected patients with metastatic non-small cell lung cancer (NSCLC).
Read more
Reference: Reinmuth et al. 2019. Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study. Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Extensive disease small cell lung cancer
CheckMate 451: Nivolumab plus ipilimumab or single-agent nivolumab did not improve overall survival
The double-blind, phase III CheckMate 451 study was designed to determine the clinical impact of the combination of nivolumab plus ipilimumab or single agent nivolumab versus placebo as maintenance therapy after first-line platinum-based chemotherapy.
Read more
Reference: Owonikoko et al. 2019. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Non-Small Cell Lung Cancer
Encouraging safety and efficacy results with afatinib in a phase III trial mimicking the real-world settings
In this phase IIIB study (N=479), patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations and with no previous treatment with EGFR tyrosine kinase inhibitors or pre-treated with chemotherapy, received a starting dose of 40 mg daily afatinib with permitted dose reduction to a minimum of 20 mg/day for a median time of 359 days.
Read more
Reference: Passaro et al. 2019. Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial. Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Non-Small Cell Lung Cancer
PD-L1 expression did not influence patient-reported outcomes in the PACIFIC study
Results from the phase III PACIFIC study (N=713) demonstrated the clinical benefit of durvalumab in patients with stage III non-small cell lung cancer (NSCLC) who did not have disease progression after platinum-based concurrent chemoradiotherapy. At ELCC 2019, Dr Garassino presented a retrospective analysis of this study aimed at determining the impact of PD-L1 expression on patient-reported outcomes (PROs).
Read more
Reference: Garassino et al. 2019. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Lung adenocarcinoma
NIS VARGADO: Nintedanib plus docetaxel as a new therapeutic option for patients progressing on immune checkpoint inhibitors
Nintedanib is an anti-angiogenic therapy that has been approved in combination with docetaxel for the treatment of locally advanced or metastatic NSCLC patients after first-line chemotherapy. Whether such a regimen is beneficial following treatment with immune checkpoint inhibitors remains unclear.
Read more
Reference: Grohe et al. 2019. Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO. Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Non-Squamous Non-Small Cell Lung Cancer
Maintenance therapy with pemetrexed is particularly effective in patients with ALK rearrangements or high PD-L1 expression
Results from this real-world study (N=102) revealed that both, the presence of anaplastic lymphoma kinase (ALK) rearrangements and high PD-L1 expression, represent potential biomarkers of response to maintenance therapy with pemetrexed in advanced non-squamous NSCLC patients.
Read more
Reference: Qin et al. 2019. PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC. Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Nonsquamous Non-Small Cell Lung Cancer
Impower150: EGFR-mutated patients benefit from the addition of atezolizumab to the standard of care
In this phase III study (N=1,202), patients were randomised 1:1:1 to arm A (atezolizumab, carboplatin and paclitaxel), arm B (atezolizumab, carboplatin, paclitaxel and bevacizumab) and arm C (carboplatin, paclitaxel and bevacizumab). Treatment was applied every 3 weeks for up to 4−6 cycles followed by maintenance therapy with atezolizumab, bevacizumab or both.
Read more
Reference: Reck et al. 2019. IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Non-Small Cell Lung Cancer
ALTA-1L: A head-to-head comparison of brigatinib vs. crizotinib
In the open-label, multicentre, phase III ALTA-1L trial, a total of 275 patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) were randomised 1:1 to receive either 180 mg brigatinib once a day with a 7-day lead-in at 90 mg or 250 mg crizotinib twice a day.
Read more
Reference: Califano et al. 2018. Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.
Non-Small Cell Lung Cancer
AURA LM: Osimertinib, at lower doses, is highly active in patients with leptomeningeal metastases 
In this study, 22 patients with leptomeningeal metastases (LM) harbouring EGFR T790M mutation and previously treated with EGFR tyrosine kinase inhibitors, received 80 mg osimertinib once daily.

Read more
Reference: Ahn et al. 2019. Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study.Oral presentation presented at: ELCC 2019 Congress; 10–13 April; Geneva, Switzerland.